Bayer Schering Fills Discovery-Development Gap Through Asian Partnering
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Drug companies are tightening their belts for discovery and development while also scanning different sectors of the globe for innovation. Bayer Schering Pharma Head of Global Drug Discovery Andreas Busch sees outside partnerships, or "externalization," as a necessity, particularly for high-risk innovation, and Bayer is looking to Asia Pacific for many of its discovery partners
You may also be interested in...
Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt
Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt
Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
Bayer Healthcare Chairman Jorg Reinhard says at BIO China that companies like Bayer must move away from their "comfort zone" and forge partnerships with Chinese companies.